Investor Presentaiton

Investor Presentation First six months of 2018 Slide 59 GLP-1 1. GLP-1 treatment 60 2. GLP-1 market growth and market share 61 3. VictozaⓇ market share 4. GLP-1 vs OAD 63 64 5. VictozaⓇ value growth and market share 65 6. GLP-1 pipeline 66 REN YANXIA Ren has type 2 diabetes China 7. OzempicⓇ 8. GLP-1 market value in Regions 67 68 9. Clinical trials (SUSTAIN & PIONEER) 74-78 novo nordisk

View entire presentation